Brown M J
University of Cambridge.
Hosp Med. 1998 Oct;59(10):808-11.
Angiotensin II receptor antagonists lower blood pressure by blocking the final step in the renin pathway, whereas ACE inhibitors reduce angiotensin II production. ACE inhibitors also block kinin degradation, which may alter both efficacy and side-effects. Irbesartan, one of the newer receptor antagonists, has confirmed their tolerability and shown similar dose-related efficacy to other major classes.
血管紧张素II受体拮抗剂通过阻断肾素途径的最后一步来降低血压，而血管紧张素转换酶（ACE）抑制剂则减少血管紧张素II的生成。ACE抑制剂还可阻断激肽降解，这可能会改变疗效和副作用。厄贝沙坦是较新的受体拮抗剂之一，已证实其耐受性良好，并显示出与其他主要类别相似的剂量相关疗效。
